Dry Eye Syndrome Market to Experience 7.0% CAGR during 2023-2030; Innovative Products to Battle Dry Eye Syndrome Will Expand Market

The global dry eye syndrome market size was valued at USD 6.61 billion in 2022. The market is projected to grow from USD 7.02 billion in 2023 to USD 11.26 billion by 2030, exhibiting a CAGR of 7.0% during the forecast period. Fortune Business Insights™ presents this information in its report titled "Dry Eye Syndrome Market" Size, Share & COVID-19 Impact Analysis, By Product (Anti-inflammatory Products {Cyclosporin, Corticosteroids, and Others}, Artificial Tears and Lubricants, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), and Regional Forecast, 2023-2030”.

Keratoconjunctivitis Sicca (KCS), commonly known as dry Eye Syndrome (DES) or Dry Eye Disease (DES), is a common ophthalmic disorder that develops when a person's tears are insufficiently healthy to lubricate or nourish the eye. Redness, stinging, itching, or burning sensations, light sensitivity, watery eyes, stringy mucus surrounding the eye, and impaired vision are some of the symptoms. According to a BMC Ophthalmology article from February 2022, people over the age of 80 were more likely to experience dry eye than patients under the age of 60 (8.4%), patients between the ages of 70 and 79 (15%), and those who reported signs of eye dryness (5–30%). Also, this disease is brought on by the lachrymal glands' diminished capacity to make tears as we age. Moreover, post-menopausal women seem to be more susceptible to the illness. Throughout the projected period, such trends will enhance the need for therapeutic interventions and support the global market expansion.

Negative Market Growth Effects were Caused by Decline in Non-Essential Treatment during COVID-19

Studies conducted during the COVID-19 outbreak showed that COVID-19 patients continued to suffer dry eye symptoms for several weeks or months after they had recovered. Due to the fact that this ocular disease is frequent, this resulted in an increase in prevalence of the problem. The prevalence of this illness has increased as a result of people increasingly moving their job and study habits from offline to online. The pandemic, on the other hand, was noted to have seen a decline in consultations for all non-essential therapeutic measures, which, in turn, led to a drop in demand for these treatments. The introduction of new sales channels in private facilities and retail establishments, however, resulted in market participants' revenues growing consistently.

Companies Focus on Newer Products to Counter the Illness

The topical anti-inflammatory and immunomodulating ophthalmic medication solution CyclASol (cyclosporine ophthalmic solution), designed for the treatment of dry eye illness, was submitted as a New Drug Application (NDA) to the U.S. FDA in August 2022.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/dry-eye-syndrome-market-102413

Dry Eye Disease Incidence on the Rise will Drive Market Growth

The substantial rise in this condition's global prevalence is one of the key factors that has a beneficial effect on the global market. With age, the likelihood of developing this chronic illness changes. Nonetheless, the prevalence is rising in both the younger and older populations due to factors such as rising screen usage, poor diet, increased contact lens wear, and rising LASIK surgery rates. The global prevalence of Dry Eye Disease (DED) ranged from 5 to 50%, according to an epidemiological study released by UpToDate, Inc. in January 2023. Due to the fact that a sizable section of the population is affected, dry eye disease has one of the highest overall costs and healthcare service demands. As the incidence of the condition rises, there will be a greater demand for more potent treatments, which will expand the global dry eye syndrome market share during the forecast period.

However, the prospective patient population's lower urgency for ocular disorders, such as dry eye syndrome, may constrain the global dry eye syndrome market growth as it might slow down the rate at which these therapies are used over the forecast period.

Competitive Landscape

Owing to its Strong Brand Recognition, AbbVie, Inc. held a Sizable Market Share in 2022

AbbVie, Inc. is one of the market's top competitors in terms of competition due to its strong brand presence and robust distribution network, particularly in the OTC artificial tears and lubricants category with its flagship brand, the Refresh series of artificial tears and lubricants. Alcon had a substantial market share in 2022 and is working to keep it by forming collaborations with other companies to broaden its line of products.

Notable Industry Development:

• May 2022: Alcon acquired EYSUVIS pharmaceutical eye drops from Kala Pharmaceuticals, Inc. to expand its product portfolio in the dry eye category.

List of Key Players Profiled in the Report

• AbbVie Inc. (Ireland)


• Alcon (Switzerland)


• Novartis AG (Switzerland)


• Santen Pharmaceutical Co., Ltd. (Japan)


• OASIS Medical (U.S.)


• Sun Pharmaceutical Industries Ltd. (India)


• Otsuka Pharmaceutical Co., Ltd. (Otsuka Holdings, Co., Ltd.) (Japan)


• Sentiss Pharma Pvt. Ltd. (India)


• Johnson & Johnson Vision Care, Inc. (Johnson & Johnson Services, Inc.) (U.S.)


• VISUfarma (Netherlands)

Further Report Findings

• As a result of the disease's increased incidence and the increasing usage of pharmaceuticals to treat it, the market for treating dry eye syndrome in North America was estimated at USD 3.10 billion in 2022 and is expected to continue dominating the industry during the projected period.


• The increase in the number of geriatric people with this illness is projected to fuel market expansion throughout the region. The Europe market is anticipated to grow with a significant CAGR over the forecast period.


• Throughout the projection period, the Asia Pacific region is anticipated to expand at the greatest CAGR. The rise in this region is primarily driven by patients' increased choice for over-the-counter medications, new drug introductions, and the condition's rising prevalence in the region.


• The projected period is expected to have lower CAGR in South America and the Middle East & Africa.

Table of Segmentation